American Association for Cancer Research (AACR) Annual Meeting 2025

Chicago, Illinois, US 25 April 2025 - 30 April 2025

Zongertinib shows antitumour activity in previously treated HER2-mutant NSCLC

29 Jun 2025 by

The oral, irreversible, HER2-selective tyrosine kinase inhibitor (TKI) zongertinib confers clinically meaningful benefit to patients with previously treated HER2-mutant nonsmall cell lung cancer (NSCLC), including those with brain metastases, while having a manageable safety profile, according to the phase 1A/1B Beamion LUNG-1 trial.

Zongertinib shows antitumour activity in previously treated HER2-mutant NSCLC

29 Jun 2025

Perioperative pembrolizumab may shift treatment paradigm in resectable HNSCC

24 Jun 2025 by

In the first interim analysis of the phase III KEYNOTE-689 trial, pembrolizumab improves event-free survival (EFS) and major pathological response (mPR) rate, independent of CPS*, when added to standard-of-care (SoC) treatment for resectable locally advanced head and neck squamous cell carcinoma (LA HNSCC).

Perioperative pembrolizumab may shift treatment paradigm in resectable HNSCC

24 Jun 2025

Penpulimab extends survival in R/M nasopharyngeal carcinoma

23 Jun 2025 by

The use of penpulimab, in combination with gemcitabine and cisplatin or carboplatin, as first-line treatment for recurrent or metastatic (R/M) nasopharyngeal carcinoma (NPC) provides statistically significant and clinically meaningful benefit, according to a study presented at AACR 2025.

Penpulimab extends survival in R/M nasopharyngeal carcinoma

23 Jun 2025